Hologic INC

Hologic, Inc. has completed its acquisition by funds managed by Blackstone and TPG, valued at up to $79 per share, with Joe Almeida appointed as the new CEO.

Hologic has secured all necessary regulatory approvals for its acquisition by Blackstone and TPG, with the transaction expected to close on April 7, 2026.

Hologic, Inc. stockholders approved the merger agreement with Blackstone and TPG, though they rejected the advisory compensation proposal for executives.

Hologic reports mixed Q1 FY26 financial results as stockholders prepare to vote on the proposed acquisition by Blackstone and TPG.

Hologic, Inc. addresses stockholder lawsuits over its merger proxy, announces a prolonged stop-ship for a key breast biopsy product, and settles BioZorb litigation.

Hologic, Inc. announced the approval of a revised Restricted Stock Unit Award Agreement by its Compensation Committee, outlining new vesting schedules and change-in-control provisions.

Hologic reports mixed first-quarter financial results with a slight revenue increase, a dip in net income, and a significant pending acquisition by Blackstone and TPG.

Hologic, Inc. reported a slight increase in quarterly net income to $194.9 million, but a substantial decline in nine-month net income to $378.5 million, primarily driven by $220.9 million in intangible asset impairment charges related to recent acquisitions.

Hologic reports a net loss for Q2 2025 due to significant intangible asset impairment charges, despite completing the acquisition of Gynesonics and experiencing revenue growth in certain segments.

Hologic's first quarter fiscal 2025 reveals a mixed performance, with diagnostics growth offsetting declines in breast health and skeletal health revenues.

Hologic's Q3 results show a mixed performance with revenue growth in some segments offset by declines in others, alongside strategic restructuring and asset sales.

Hologic's second quarter results show a decrease in revenue compared to the prior year, primarily due to declining COVID-19 assay sales, alongside strategic restructuring and asset sales.

Hologic, Inc. filed an amendment to its annual report, providing detailed executive compensation, corporate governance updates, and the impact of its recent merger on equity awards.

Hologic, Inc. reported a 1.7% revenue increase to $4.1 billion in fiscal 2025, but net income fell 28.3% to $565.7 million, impacted by significant impairment charges and restructuring costs, as the company progresses towards a proposed acquisition by Blackstone and TPG.

Hologic's 2024 annual report reveals a slight decrease in product revenue, offset by growth in Breast Health and GYN Surgical, while navigating challenges in Diagnostics and Skeletal Health.

Hologic, Inc. has completed its merger, resulting in significant changes to executive beneficial ownership of company securities.

Brandon Schnittker reports on changes in beneficial ownership of Hologic Inc. following a merger, detailing the conversion of stock options and units into cash and contingent value rights.

Jennifer M. Schneiders reports on changes in beneficial ownership following Hologic Inc.'s merger, with stock options and performance units converted to cash and contingent value rights.

Hologic Inc. Chief Financial Officer Karleen Marie Oberton reports on changes in beneficial ownership following the company's merger.

Hologic's Chief Operating Officer, Mitchell Essex, filed a Form 4 detailing transactions related to the company's merger, including the conversion of stock options and performance units into merger consideration.

Hologic Inc. has completed its merger, resulting in changes to executive beneficial ownership and the conversion of stock options and units into cash and contingent value rights.

Hologic, Inc. filed a definitive additional proxy statement to address stockholder lawsuits regarding its merger disclosures and announced a voluntary recall of its Brevera Breast Biopsy System needles.

Hologic, Inc. provides employees with an FAQ detailing the impact of its pending acquisition by Blackstone and TPG on unvested RSUs, stock options, and ESPP, along with general company operations post-merger.

Hologic, Inc. stockholders are invited to a special meeting on February 5, 2026, to vote on a merger agreement with affiliates of Blackstone and TPG, offering $76.00 cash plus a CVR up to $3.00 per share.

Hologic, Inc. issued an internal FAQ to employees detailing the impact of its acquisition by Blackstone and TPG on benefits, bonuses, and equity awards.

Hologic, Inc. announced its unanimous board-approved acquisition by Blackstone and TPG, aiming to accelerate growth as a private company.

Hologic, Inc. announced robust fiscal fourth-quarter results with significant revenue and EPS growth, alongside a definitive agreement to be acquired by Blackstone and TPG for up to $79 per share.

Vanguard Capital Management has reported a beneficial ownership of 7.49% in Hologic Inc. common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G for Hologic Inc., reporting 0% beneficial ownership following an internal realignment that shifts reporting to its subsidiaries.

T. Rowe Price Investment Management, Inc. has disclosed an updated beneficial ownership of 9.7% in Hologic Inc., holding over 21.5 million common shares.

T. Rowe Price Investment Management, Inc. has disclosed a significant beneficial ownership stake of 10.8% in Hologic Inc., totaling over 24 million shares of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a passive beneficial ownership of 8.9% of Hologic Inc.'s common stock as of March 31, 2025.

T. Rowe Price Investment Management, Inc. has filed an updated Schedule 13G, revealing a 7.9% beneficial ownership stake in Hologic Inc.'s common stock as of December 31, 2024.